Revance to Participate in Upcoming Investor Conferences

Rhea-AI Impact
Rhea-AI Sentiment
(Very Positive)

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (RVNC) today announced that the company will be participating in the following investor conferences.

William Blair 43rd Annual Growth Stock Conference

Chief Executive Officer Mark J. Foley is scheduled to participate in a fireside chat on Tuesday, June 6, 2023, at 4:00 P.M. CDT, in Chicago, Illinois.

Goldman Sachs 44th Annual Global Healthcare Conference

Chief Executive Officer Mark J. Foley and President Dustin S. Sjuts are scheduled to participate in a fireside chat on Monday, June 12, 2023, at 8:40 A.M. PDT, in Dana Point, California.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.

About Revance

Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that elevate patient and physician experiences. Revance’s aesthetics portfolio of expertly created products and services, including DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers, and OPUL®, the first-of-its-kind Relational Commerce platform for aesthetic practices, deliver a differentiated and exclusive offering for the company’s elite practice partners and their consumers. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection, which will compete in the existing short-acting neuromodulator marketplace. Revance’s therapeutics pipeline is currently focused on muscle movement disorders including evaluating DAXXIFY® in two debilitating conditions, cervical dystonia and upper limb spasticity.

Revance is headquartered in Nashville, Tennessee, with additional office locations in Newark, Pleasanton and Irvine, California. Learn more at,,, or connect with us on LinkedIn.

“Revance” and the Revance logo, DAXXIFY®, and OPUL® are registered trademarks of Revance Therapeutics, Inc.
Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.


Revance Therapeutics, Inc.:

Jessica Serra, 510-279-6886


Gilmartin Group, LLC.:

Laurence Watts, 619-916-7620


Revance Therapeutics, Inc.:

Sara Fahy, 949-887-4476

Source: Revance Therapeutics, Inc.

Revance Therapeutics Inc


RVNC Rankings

RVNC Latest News

RVNC Stock Data

Pharmaceutical Preparation Manufacturing
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
United States

About RVNC

revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form